Why the study?
Does glimepiride have less adverse cardiovascular activity compared to conventional sulfonylureas in preclinical models?
Does glimepiride have less adverse cardiovascular activity compared to conventional sulfonylureas in preclinical models?
In preclinical models, the newer sulfonylurea glimepiride exhibits significantly less adverse cardiovascular activity compared to conventional agents like glibenclamide and gliclazide.
Authors
No takes yet. Share an insight, caveat, or question.
May inform sulfonylurea selection in cardiovascular patients; leaves open clinical translation pending human trials.
Geisen et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: